AKT Inhibition in Prostate Cancer — Proceedings from a Session Held Adjunct to the 2026 ASCO Genitourinary Cancers Symposium
Oncology Today with Dr Neil Love
00:00
Rationale for AKT Targeting in Prostate Cancer
Karim Fizazi explains AR–AKT crosstalk and preclinical rationale for dual pathway targeting.
Play episode from 33:25
Transcript
